Lesson
Let the Person Define the Goal
Gender-affirming care does not require one binary endpoint or one standard regimen. The person defines meaningful changes while the clinical team explains what hormones can and cannot control, what may be irreversible, and how the plan will be monitored.
- Person-defined goals
- Informed choice
- Nonbinary regimens
- Effect timelines
- Irreversibility
- Youth care boundary
Identify what matters now and what remains optional
Separate likely, variable, coupled, and lasting effects
Match formulation and tempo to goals and access
Update the plan as experience, health, and identity change
Begin with the desired change
Ask which physical, sexual, reproductive, emotional, and social outcomes matter now. A person may want broad feminization or masculinization, a subset of effects, slower change, or no hormone treatment.
Explain coupled effects
Dose and route can influence pace and magnitude, but hormones do not reliably isolate one tissue. Voice deepening, facial hair, breast development, gonadal suppression, fertility change, and sexual effects differ in reversibility.
Use informed choice as a process
Discuss benefits, limits, alternatives, formulation technique, monitoring, fertility, contraception, uncertainty, and urgent symptoms. Revisit consent when goals, anatomy, health, access, or treatment change.
State the regulatory boundary
Common estradiol, testosterone, and adjunct products generally are not FDA approved specifically for gender affirmation in the United States. Off-label use can be evidence-informed, but the labeled indication, guideline evidence, product warnings, and monitoring should be distinguished clearly.
Avoid a laboratory-only endpoint
A concentration supports dosing and safety but cannot define identity or satisfaction. Clinical response, adverse effects, correct administration, assay timing, and the person's goals remain central.
Route youth care appropriately
Prepubertal and adolescent treatment involves development, consent, fertility, bone, family and social context, and local requirements. It belongs with an experienced multidisciplinary team rather than an adult regimen copied downward.
Quick check
Lesson
Build the Baseline Around the Regimen
Baseline care identifies risks that estradiol, testosterone, gonadal suppression, or adjunctive medicines could worsen and converts them into a safer plan. It also protects fertility and contraceptive choice before exposure changes reproductive function.
- Clinical inventory
- Medication reconciliation
- Fertility preservation
- Contraception
- Regimen-specific laboratory tests
- Access barriers
Find modifiable risks without pathologizing identity
Discuss gametes and reproductive goals before exposure
Use anatomy and sexual practices rather than assumptions
Order CBC, potassium, kidney, hormone, or metabolic tests with purpose
Inventory health without pathologizing identity
Review blood pressure, tobacco, VTE, cardiovascular disease, diabetes, lipids, liver and kidney disease, sleep apnea, cancer history, mental health, medications, anatomy, prior treatment, and the ability to return.
Stabilize rather than exclude
Address acute or unstable conditions and modify risk while preserving access whenever possible. A history of risk usually changes route, monitoring, or coordination rather than ending the discussion.
Discuss fertility before exposure
Estradiol, androgen suppression, testosterone, and gonadal surgery can reduce gametogenesis unpredictably. Offer timely information about sperm, oocyte, embryo, or tissue preservation without assuming a parenting goal.
Separate hormones from contraception
Amenorrhea and reduced sperm production do not prove infertility. Ask about retained organs and sexual practices, then offer pregnancy prevention and STI protection according to the person's preferences.
Order decision-linked tests
CBC is central before and during testosterone. Potassium and kidney function matter with spironolactone. Hormone, pregnancy, metabolic, and organ testing should answer specific regimen and health questions.
Quick check
Lesson
Design Estradiol by Molecule and Route
Estradiol route changes absorption, first-pass exposure, peaks, adherence, and thrombotic context. Safe selection avoids obsolete high-risk estrogen choices and uses formulation-aware laboratory interpretation rather than comparing dose numbers directly.
- 17 beta estradiol
- Oral route
- Transdermal route
- Injectable route
- VTE risk
- Laboratory timing
Avoid ethinyl estradiol and obsolete high-risk substitution
Compare first pass, stability, peaks, technique, and access
Prefer transdermal delivery when age or VTE history raises concern
Read estradiol and testosterone beside dose timing and goals
Use estradiol, not contraceptive ethinyl estradiol
WPATH recommends against ethinyl estradiol for feminizing therapy. It also advises against conjugated estrogens when estradiol is available because exposure is harder to monitor and thrombotic evidence is less favorable.
Compare routes, not just doses
Oral estradiol undergoes first-pass hepatic exposure. Transdermal delivery produces steadier systemic delivery and is preferred by WPATH for people older than 45 years or with previous VTE. Injectable products can create larger peak and trough variation.
Build a VTE strategy
Review prior VTE, thrombophilia, smoking, immobility, surgery, cancer, obesity, family history, and anticoagulation. Modify risk and coordinate complex histories rather than defaulting to unsafe exposure or automatic denial.
Interpret the concentration in time
Document route, exact product, dose, last administration, and collection time. Estradiol and testosterone concentrations are interpreted with physical response, adverse effects, adherence, and the assay.
Avoid supraphysiologic escalation
Slow breast or body-composition change can reflect normal biology. Increasing estradiol beyond physiologic targets does not guarantee more desired change and can add risk.
Quick check
Lesson
Choose Androgen Reduction by Mechanism
Androgen-reducing medicines act at different sites. Spironolactone, GnRH analogues, and 5-alpha reductase inhibitors are not interchangeable, and progestogens do not belong automatically in every feminizing regimen.
- Spironolactone
- GnRH analogues
- 5-alpha reductase
- Progestogen uncertainty
- Gonadal status
- Targeted adjuncts
Join androgen goals to kidney, potassium, and pressure safety
Reduce gonadal production with calendar and bone awareness
Target dihydrotestosterone without broad suppression
Require a defined benefit, evidence boundary, and stop rule
Keep spironolactone's full pharmacology
Its antiandrogen role coexists with mineralocorticoid receptor antagonism. Review potassium, kidney function, pressure, orthostasis, volume status, and other potassium-raising medicines.
Use GnRH therapy deliberately
GnRH analogues can suppress gonadal hormone production effectively but differ in onset and delivery and can be costly. Bone, fertility, gonadal status, dosing calendar, and access shape their use.
Set limits for 5-alpha reductase inhibition
Finasteride and dutasteride reduce conversion of testosterone to dihydrotestosterone. They may support a scalp-hair goal but do not provide broad testosterone suppression.
Do not add progestogens by reflex
SOC8 did not identify enough evidence to recommend routine progestogen use for feminizing therapy. A proposed breast, mood, sleep, or sexual goal should be balanced against uncertain benefit and product-specific risk.
Audit before stacking medicines
Persistent testosterone can reflect adherence, administration, timing, assay, dose, gonadal production, or interaction. Confirm the mechanism before adding another agent.
Quick check
Lesson
Read Feminizing Response as a System
Breast development, body composition, skin, muscle, erections, libido, hair, gonadal function, mood, and sexual experience change at different rates. Follow-up links those outcomes to exposure and safety rather than chasing one laboratory number.
- Effect timelines
- Estradiol and testosterone
- VTE surveillance
- Cardiometabolic risk
- Prolactin symptoms
- Response audit
Track breast, body, skin, hair, sexual, and mood outcomes
Time values to route and administration
Separate acute emergency assessment from routine monitoring
Verify product, technique, access, assay, and goal before escalation
Expect different tissue clocks
Skin and sexual function may change earlier than breast tissue or body composition. Hair response can be incomplete and may require separate cosmetic treatment. Final outcomes vary even with similar concentrations.
Use laboratories with the clinical story
Review estradiol and testosterone with route, dose timing, adherence, and goals. An isolated value cannot prove correct administration or explain every physical outcome.
Triage acute vascular symptoms
New unilateral leg swelling, chest pain, dyspnea, severe headache, or neurologic symptoms require urgent assessment. Routine follow-up testing is not a substitute for acute evaluation.
Monitor supported risks
Follow blood pressure and conventional cardiovascular risk. Check metabolic parameters by standard indications, spironolactone safety by renal context, and prolactin when symptoms or the monitoring framework support it.
Audit before escalating
Verify products, technique, refill access, administration, laboratory timing, gonadal status, and the actual desired outcome before increasing estradiol or stacking adjuncts.
Quick check
Lesson
Treat Each Testosterone Product as Its Own System
Testosterone formulations differ in concentration, route, interval, peaks, troughs, transfer risk, procedure burden, and current labeling. Safe care matches the product to the person and times laboratory interpretation to the formulation.
- Injectable testosterone
- Transdermal testosterone
- Product concentration
- Peak and trough
- Erythrocytosis
- Blood pressure
Prevent cross-product dose and route errors
Protect sterile use, sharps, drying, covering, and transfer
Label the laboratory result with the dosing clock
Address erythrocytosis, hypoxia, pressure, and product risk
Verify the product every time
Cypionate, enanthate, undecanoate, gels, patches, oral, buccal, and implantable products are not interchangeable. Concentration and device differences can create large errors.
Teach route-specific safety
Injection care includes sterile technique and sharps disposal. Gels require drying, covering, handwashing, and prevention of secondary transfer. Long-acting products may require supervised administration.
Time the concentration
Record the last dose and laboratory time. Mid-interval, peak, and trough results answer different questions for injectable products, while transdermal interpretation depends on correct application and product guidance.
Treat hematocrit as a mechanism signal
Confirm elevation and assess dose, interval, dehydration, smoking, altitude, pulmonary disease, and sleep apnea. Modify exposure and investigate cause rather than relying on repeated phlebotomy alone.
Use the current blood pressure warning
FDA removed older boxed cardiovascular language in 2025 but added class-wide blood pressure warnings after ambulatory studies showed increases across testosterone products. Monitor and treat pressure accordingly.
Quick check
Lesson
Investigate the Outcome, Not Only the Dose
Voice, hair, body composition, skin, libido, clitoral tissue, menses, genital tissue, fertility, mood, and sexual health respond differently to testosterone. Persistent bleeding or symptoms require a differential diagnosis rather than reflex dose escalation.
- Effect timelines
- Irreversible effects
- Persistent bleeding
- Genital tissue
- Acne and alopecia
- Response audit
Separate reversible and lasting voice, hair, skin, and body effects
Consider exposure, pregnancy, infection, and structural causes
Address dryness, pain, urinary symptoms, and pelvic function
Verify technique, timing, CBC, pressure, sleep, and goals
Explain tissue-specific reversibility
Voice deepening, facial hair, and some genital changes may not reverse after stopping testosterone. Muscle, fat distribution, skin oil, and menstrual effects may change again when exposure changes.
Evaluate bleeding
Persistent or recurrent uterine bleeding can reflect exposure, pregnancy, structural disease, infection, atrophy, or endometrial pathology. Evaluate the pattern and anatomy before changing testosterone.
Care for genital tissue
Dryness, tearing, dyspareunia, urinary symptoms, and discharge may involve tissue atrophy, infection, pelvic floor pain, or structural disease. Offer trauma-informed examination and local care when appropriate.
Treat adverse effects specifically
Acne, scalp hair loss, sleep symptoms, mood change, edema, pressure increase, and erythrocytosis require targeted evaluation. Not every adverse effect improves by lowering or raising the hormone.
Audit the exposure system
Confirm product, concentration, technique, timing, adherence, assay, CBC, pressure, and the desired outcome before intensifying treatment.
Quick check
Lesson
Keep Reproductive Care Inside Hormone Care
Fertility can decline, recover incompletely, or persist despite hormone therapy. Pregnancy and contraception decisions therefore remain active before, during, and after treatment and must be based on anatomy and exposure.
- Fertility preservation
- Contraception
- Pregnancy
- Menstrual suppression
- Gamete recovery
- Sexual health
Protect future options without assuming a parenting goal
Hormones and amenorrhea do not replace contraception
Stop testosterone in pregnancy and treat bleeding directly
Use specialist care because recovery is variable
Do not promise fertility recovery
Sperm or ovulation may return after hormones stop, but timing and completeness vary. Early preservation counseling protects options that later treatment cannot guarantee.
Offer contraception by eligibility and preference
Testosterone and GnRH therapy are not contraception. Hormonal IUDs, implants, injections, pills, and nonhormonal methods can be considered according to medical eligibility, bleeding goals, dysphoria, and preference.
Protect pregnancy
Testosterone should not be used during pregnancy. Stop it when pregnancy is identified or actively pursued and coordinate reproductive, obstetric, and dysphoria support.
Treat bleeding goals directly
Menstrual suppression can be added when testosterone alone does not meet the goal or is not desired. Choice follows contraception needs, bone health, VTE risk, insertion tolerance, and the person's priorities.
Use anatomy and practices for sexual health
STI prevention, screening, contraception, pain, lubrication, erectile function, and fertility counseling should follow tissues and exposures without assumptions about partner gender or anatomy.
Quick check
Lesson
Screen the Person and the Organs Present
Long-term care integrates hormone pharmacology with standard prevention. Cancer screening, bone health, cardiovascular care, and symptom evaluation follow the organs present, exposure history, age, family history, and conventional risk factors.
- Organ inventory
- Cancer screening
- Bone health
- Cardiovascular prevention
- Metabolic health
- Aging
Record tissues, surgery, hormone exposure, and preferred language
Apply current tissue-specific guidance
Prevent prolonged hypogonadism and assess fracture risk
Treat standard risks plus route, pressure, and hematocrit effects
Maintain an organ inventory
Record breast or chest tissue, cervix, uterus, ovaries, prostate, testes, surgical history, hormone exposure, prior dysplasia or cancer, and the person's preferred language for care.
Screen by tissue and risk
Apply current age, symptom, family, genetic, and tissue-specific guidance. A gender marker should not omit needed screening or generate irrelevant procedures.
Assess bone by mechanism
Prolonged hypogonadism, inadequate hormone exposure after gonadectomy, fractures, low weight, glucocorticoids, smoking, age, and conventional risks guide DXA and prevention.
Use standard cardiovascular prevention
Treat tobacco, blood pressure, diabetes, lipids, sleep apnea, activity, and nutrition. Add regimen-specific attention to estrogen route, VTE, testosterone pressure effects, and hematocrit.
Investigate symptoms promptly
New bleeding, breast or chest mass, testicular change, urinary symptoms, pelvic pain, or unexplained constitutional symptoms require anatomy-directed evaluation regardless of identity.
Quick check
Lesson
Protect Continuity Through Every Transition
Hospitalization, surgery, incarceration, travel, insurance loss, and stigma can interrupt hormone care. Medication reconciliation and harm reduction preserve physical safety, gonadal health, trust, and access without assuming one universal perioperative stop rule.
- Medication reconciliation
- Perioperative planning
- Acute illness
- Self-sourced hormones
- Harm reduction
- Access and transfer
Preserve concentration, route, interval, and monitoring
Balance interruption harm with procedure-specific risk
Replace punishment with safer products, testing, and trust
Document next dose, warnings, tests, and responsibility
Reconcile exact products
Record name, concentration, route, dose, interval, last administration, supply, pharmacy, adjuncts, and monitoring. Similar product names do not guarantee interchangeable instructions.
Individualize perioperative management
Consider procedure, immobility, prior VTE, estrogen route, smoking, anticoagulation, gonadal status, withdrawal effects, postoperative intake, and the surgeon's protocol rather than stopping every hormone automatically.
Protect post-gonadectomy exposure
A prolonged interruption after gonadectomy can create symptomatic hypogonadism and bone risk. If treatment must pause, define the reason, duration, alternative, and restart ownership.
Use harm reduction for self-sourced therapy
Ask without punishment about product, source, dose, route, equipment, sharing, symptoms, and access. Offer reliable prescribing, testing, injection safety, and urgent evaluation when needed.
Design the handoff
At discharge or transfer, document the regimen, pending tests, next dose, monitoring, warning signs, supply, and clinician responsible for follow-up.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 148 question bank.
Each attempt draws a fresh set and rearranges the answer choices.